These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 33923431)

  • 21. Pleiotropic Anti-atherosclerotic Effects of PCSK9 InhibitorsFrom Molecular Biology to Clinical Translation.
    Karagiannis AD; Liu M; Toth PP; Zhao S; Agrawal DK; Libby P; Chatzizisis YS
    Curr Atheroscler Rep; 2018 Mar; 20(4):20. PubMed ID: 29525934
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential effects of red yeast rice, Berberis aristata and Morus alba extracts on PCSK9 and LDL uptake.
    Lupo MG; Macchi C; Marchianò S; Cristofani R; Greco MF; Dall'Acqua S; Chen H; Sirtori CR; Corsini A; Ruscica M; Ferri N
    Nutr Metab Cardiovasc Dis; 2019 Nov; 29(11):1245-1253. PubMed ID: 31439394
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Liraglutide blocks the proliferation, migration and phenotypic switching of Homocysteine (Hcy)-induced vascular smooth muscle cells (VSMCs) by suppressing proprotein convertase subtilisin kexin9 (PCSK9)/ low-density lipoprotein receptor (LDLR).
    Ji J; Feng M; Niu X; Zhang X; Wang Y
    Bioengineered; 2021 Dec; 12(1):8057-8066. PubMed ID: 34666623
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K; Sharma M; Ferdinand KC
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Thyroid stimulating hormone exhibits the impact on LDLR/LDL-c via up-regulating hepatic PCSK9 expression.
    Gong Y; Ma Y; Ye Z; Fu Z; Yang P; Gao B; Guo W; Hu D; Ye J; Ma S; Zhang F; Zhou L; Xu X; Li Z; Yang T; Zhou H
    Metabolism; 2017 Nov; 76():32-41. PubMed ID: 28987238
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of the effects of natural isoquinoline alkaloids on low density lipoprotein receptor (LDLR) and proprotein convertase subtilisin/kexin type 9 (PCSK9) in hepatocytes, as new potential hypocholesterolemic agents.
    Maharjan B; Payne DT; Ferrarese I; Giovanna Lupo M; Kumar Shrestha L; Hill JP; Ariga K; Rossi I; Sharan Shrestha S; Panighel G; Lal Swagat Shrestha R; Sut S; Ferri N; Dall'Acqua S
    Bioorg Chem; 2022 Apr; 121():105686. PubMed ID: 35217376
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pitavastatin inhibits lysophosphatidic acid-induced proliferation and monocyte chemoattractant protein-1 expression in aortic smooth muscle cells by suppressing Rac-1-mediated reactive oxygen species generation.
    Kaneyuki U; Ueda S; Yamagishi S; Kato S; Fujimura T; Shibata R; Hayashida A; Yoshimura J; Kojiro M; Oshima K; Okuda S
    Vascul Pharmacol; 2007 Apr; 46(4):286-92. PubMed ID: 17178255
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PCSK9 in cholesterol metabolism: from bench to bedside.
    Reiss AB; Shah N; Muhieddine D; Zhen J; Yudkevich J; Kasselman LJ; DeLeon J
    Clin Sci (Lond); 2018 Jun; 132(11):1135-1153. PubMed ID: 29895529
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The transition of smooth muscle cells from a contractile to a migratory, phagocytic phenotype: direct demonstration of phenotypic modulation.
    Sandison ME; Dempster J; McCarron JG
    J Physiol; 2016 Nov; 594(21):6189-6209. PubMed ID: 27393389
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting PCSK9 as a promising new mechanism for lowering low-density lipoprotein cholesterol.
    Della Badia LA; Elshourbagy NA; Mousa SA
    Pharmacol Ther; 2016 Aug; 164():183-94. PubMed ID: 27133571
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Proprotein convertase subtilisin/kexin 9 inhibitors: an emerging lipid-lowering therapy?
    Dragan S; Serban MC; Banach M
    J Cardiovasc Pharmacol Ther; 2015 Mar; 20(2):157-68. PubMed ID: 24938457
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New CETP inhibitor K-312 reduces PCSK9 expression: a potential effect on LDL cholesterol metabolism.
    Miyosawa K; Watanabe Y; Murakami K; Murakami T; Shibata H; Iwashita M; Yamazaki H; Yamazaki K; Ohgiya T; Shibuya K; Mizuno K; Tanabe S; Singh SA; Aikawa M
    Am J Physiol Endocrinol Metab; 2015 Jul; 309(2):E177-90. PubMed ID: 26015437
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A G/C element mediates repression of the SM22alpha promoter within phenotypically modulated smooth muscle cells in experimental atherosclerosis.
    Wamhoff BR; Hoofnagle MH; Burns A; Sinha S; McDonald OG; Owens GK
    Circ Res; 2004 Nov; 95(10):981-8. PubMed ID: 15486317
    [TBL] [Abstract][Full Text] [Related]  

  • 34. SM22α (Smooth Muscle Protein 22-α) Promoter-Driven IGF1R (Insulin-Like Growth Factor 1 Receptor) Deficiency Promotes Atherosclerosis.
    Sukhanov S; Higashi Y; Shai SY; Snarski P; Danchuk S; D'Ambra V; Tabony M; Woods TC; Hou X; Li Z; Ozoe A; Chandrasekar B; Takahashi SI; Delafontaine P
    Arterioscler Thromb Vasc Biol; 2018 Oct; 38(10):2306-2317. PubMed ID: 30354209
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of PCSK9 in lipid metabolism and atherosclerosis.
    Lin XL; Xiao LL; Tang ZH; Jiang ZS; Liu MH
    Biomed Pharmacother; 2018 Aug; 104():36-44. PubMed ID: 29758414
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Lipid-lowering drugs and PCSK9].
    Millán Núñez-Cortés J; Mostaza Prieto JM
    Clin Investig Arterioscler; 2016 May; 28 Suppl 2():9-13. PubMed ID: 27888906
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Black Raspberry Extract Enhances LDL Uptake in HepG2 Cells by Suppressing PCSK9 Expression to Upregulate LDLR Expression.
    Song KH; Kim YH; Im AR; Kim YH
    J Med Food; 2018 Jun; 21(6):560-567. PubMed ID: 29569973
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relationship Between Low-Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid-Lowering Strategies.
    Rey J; Poitiers F; Paehler T; Brunet A; DiCioccio AT; Cannon CP; Surks HK; Pinquier JL; Hanotin C; Sasiela WJ
    J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27287699
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hemodynamic shear stress via ROS modulates PCSK9 expression in human vascular endothelial and smooth muscle cells and along the mouse aorta.
    Ding Z; Liu S; Wang X; Deng X; Fan Y; Sun C; Wang Y; Mehta JL
    Antioxid Redox Signal; 2015 Mar; 22(9):760-71. PubMed ID: 25490141
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enhanced pro-protein convertase subtilisin/kexin type 9 expression by C-reactive protein through p38MAPK-HNF1α pathway in HepG2 cells.
    Cui CJ; Li S; Zhu CG; Sun J; Du Y; Zhang Y; Wu NQ; Guo YL; Xu RX; Gao Y; Li JJ
    J Cell Mol Med; 2016 Dec; 20(12):2374-2383. PubMed ID: 27633999
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.